雷贝拉唑钠(Rabeprazole Sodium) - 药物靶点：Proton pump_在研适应症：糜烂性胃食管反流病，幽门螺杆菌感染，螺杆菌感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Rabeprazole Na、Rabeprazole sodium (JP17/USP)、Sodium Rabeprazole

+ [21]

靶点

Proton pump

作用机制

质子泵抑制剂

治疗领域

肿瘤感染消化系统疾病+ [4]

在研适应症

糜烂性胃食管反流病幽门螺杆菌感染螺杆菌感染+ [5]

非在研适应症

吻合口溃疡反流性食管炎良性胃溃疡+ [6]

原研机构

Eisai Co., Ltd.

在研机构

江苏豪森医药研究院有限公司

Genuone Sciences, Inc.CHARTWELL RX SCIENCES LLC

+ [4]

非在研机构

Eisai Co., Ltd.Teva Pharmaceuticals USA, Inc.

Aytu Biopharma, Inc.

+ [7]

最高研发阶段批准上市

首次获批日期

美国 (1999-08-19),

十二指肠溃疡胃食管反流Zollinger-Ellison综合征

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C18H21N3O3S

InChIKeyYREYEVIYCVEVJK-UHFFFAOYSA-N

CAS号117976-89-3

查看全部结构式(3)

关联

179

项与雷贝拉唑钠相关的临床试验

NCT06481371 / Not yet recruitingN/AIIT

A Single-centre Randomised Controlled Study of 4-week Zuojin Pills in Combination With Sodium Rabeprazole Enteric-coated Tablets or Mosapride Citrate for the Treatment of Functional Dyspepsia Combined With Depression

To evaluate the symptom improvement of Zuojinwan combined with rabeprazole or Zuojinwan combined with a mosapride regimen in patients with functional dyspepsia combined with depression (liver-stomach depression-heat type) using rabeprazole or mosapride regimen as a control, and to compare the patients' adherence to the medication and the adverse effects between the two groups.

开始日期2024-06-30

申办/合作机构

南京医科大学第一附属医院

NCT06417229 / Recruiting临床1期

A Phase 1, Two-part, Open-label Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BMS-986365, Food and Proton Pump Inhibitor Effects, and Relative Bioavailability of BMS-986365 Capsule Compared to Tablet Formulation in Healthy Adult Male Participants

The purpose of this study is to evaluate the safety, tolerability, drug levels, food effects and relative bioavailability of BMS-986365 in healthy male participants.

开始日期2024-05-28

申办/合作机构

Celgene Corp.

NCT06264440 / Completed临床1期

A Phase 1, Open-Label, Crossover Study to Assess the Potential for Gastric pH-Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

The primary objective of the study is to evaluate the effects of a proton pump inhibitor (PPI) [rabeprazole] on BIIB122 pharmacokinetics (PK) after a single dose in healthy participants. The secondary objective of the study is to evaluate the safety and tolerability of BIIB122, with and without a PPI (rabeprazole), after a single dose in healthy participants.

开始日期2024-02-12

申办/合作机构

Biogen, Inc.

100 项与雷贝拉唑钠相关的临床结果

登录后查看更多信息

100 项与雷贝拉唑钠相关的转化医学

登录后查看更多信息

100 项与雷贝拉唑钠相关的专利（医药）

登录后查看更多信息

145

项与雷贝拉唑钠相关的文献（医药）

2024-10-01·International Journal of Toxicology

13-Week Repeated Oral Toxicity and Toxicokinetic Studies of Rabeprazole Sodium and Sodium Bicarbonate Combination in Dogs

Article

作者: Hwang, Eui-Kyung ; Nam, Kyu-Yeol ; Kim, Young-Min ; Roh, Jae Seok ; Jeon, Tae-Won ; Jung, Won Tae

The subchronic toxicity and toxicokinetics of a combination of rabeprazole sodium and sodium bicarbonate were investigated in dogs by daily oral administration for 13 consecutive weeks with a 4-week recovery period. The dose groups consisted of control (vehicles), (5 + 200), (10 + 400), and (20 + 800) mg/kg of rabeprazole sodium + sodium bicarbonate, 20 mg/kg of rabeprazole sodium only, and 800 mg/kg of sodium bicarbonate only. Esophageal ulceration accompanied by inflammation was observed in only one animal in the male (20 + 800) mg/kg rabeprazole sodium + sodium bicarbonate group. However, the severity of the ulceration was moderate, and the site of occurrence was focally extensive; thus, it was assumed to be a treatment-related effect of rabeprazole sodium + sodium bicarbonate. In the toxicokinetics component of this study, systemic exposure to rabeprazole sodium (AUClast and Cmax at Day 91) was greater in males than females, suggesting sex differences. AUClast and Cmax at Day 91 were increased compared to those on Day 1 in a dose-dependent manner. A delayed Tmax and no drug accumulation were observed after repeated dosage. In conclusion, we suggest under the conditions of this study that the no-observed-adverse-effect level (NOAEL) of the combination of rabeprazole sodium + sodium bicarbonate in male and female dogs is (10 + 400) and (20 + 800) mg/kg, respectively.

2024-06-01·Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

[Protective effect of Albizia chinensis saponin on ethanol-induced gastric mucosal injury in rats focus on mucus and mucosal barriers].

Article

作者: Zhang, Jian-Jun ; Jia, Xiao-Yu

This study aims to explore the protective effect of Albizia chinensis saponin on ethanol-induced acute gastric ulcer in rats and elucidate its mechanisms. SD rats were deprived of water for 24 hours before the experiment. The control group and model group were administered water by gavage, and the positive drug group received rabeprazole sodium solution(40 mg·kg~(-1)) by gavage. The experimental groups were given different doses of Albizia chinensis saponin solution(3, 10, and 30 mg·kg~(-1)). After 30 minutes, the control group received 1.5 mL of water by gavage, while the other groups were administered an equal volume of 95% ethanol for modeling. After six hours, the rats were killed by cervical dislocation, and the stomachs were collected. The ulcer area was measured, and the ulcer index was calculated. Hematoxylin-eosin(HE) staining was performed to assess histopathological changes in gastric tissue. Periodic acid-Schiff(PAS) staining was used to evaluate the distribution of gastric mucosal surface mucus. Enzyme-linked immunosorbent assay(ELISA) was employed to measure the levels of phospholipids and aminohexose in the gastric mucosa. Western blot was performed to determine the expression levels of the bicarbonate transporter, matrix metalloproteinase, and tight junction-associated proteins in gastric tissue. Immunohistochemistry(IHC) staining was conducted to quantify the number of positive cells for secreted mucin and tight junction-associated proteins. The results showed that the gastric tissue surface of rats in the control group was smooth without ulceration, and the gastric ulcer index of rats in the model group was 35±11. Albizia chinensis saponin at doses of 3, 10, and 30 mg·kg~(-1) resulted in inhibition rates of gastric ulcer of 46%(P<0.01), 85%(P<0.001), and 100%(P<0.001), respectively. Severe disruption of gastric mucosal structure and absence of the mucus layer were observed in the model group. Compared with the model group, the Albizia chinensis saponin group showed intact gastric mucosal surface mucus layer, significantly increased levels of phospholipids and aminohexose in the mucus, increased number of MUC5AC positive cells, and upregulated expression levels of the bicarbonate transporter SLC26A3 and CFTR. It also showed decreased phosphorylation of JNK and c-Jun, reduced expression levels of MMP-8, elevated expression of TIMP-1, and increased expression levels of Occludin and ZO-1. In conclusion, Albizia chinensis saponin enhances the function of the mucus-bicarbonate barrier by upregulating the content of MUC5AC, phospholipids, and aminohexose and increasing the expression levels of the bicarbonate transporter SLC26A3 and CFTR. Moreover, Albizia chinensis saponin exerts its protective effects on gastric ulcers by inhibiting the JNK signaling pathway to prevent excessive activation of MMP-8, thereby reducing the degradation of Occludin and ZO-1 and enhancing the mucosal barrier function. In summary, Albizia chinensis saponin exerts its anti-gastric ulcer effects by simultaneously enhancing the mucus barrier and the mucosal barrier.

2024-06-01·The Lancet Infectious Diseases

Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials

Article

作者: Lou, Jinfeng ; Wang, Jing ; Ma, Zhenkun ; Wang, Meng ; Geng, Guozhu ; Liu, Yusi ; Chen, Hong ; Gao, Lei ; Li, Xiaojiao ; Chen, Jing ; Zhang, Hong ; Wu, Min ; Ding, Yanhua ; Liu, Jingrui

BACKGROUNDDue to the rapid development of antimicrobial resistance, the efficacy of most Helicobacter pylori eradication therapies have progressively decreased to an unacceptable level. Rifasutenizol (TNP-2198) is a new molecular entity with a synergistic dual mechanism of action currently under clinical development for the treatment of microaerophilic and anaerobic bacterial infections. We aimed to evaluate the safety, pharmacokinetics, and efficacy of rifasutenizol in healthy Chinese participants and patients with H pylori.METHODSWe conducted four clinical trials of rifasutenizol capsules in healthy participants (aged 18-55 years) and patients with asymptomatic H pylori infection (aged 18-65 years) in a clinical trial centre in Jilin province, China. Trial 1 was a phase 1, double-blind, randomised, placebo-controlled, single ascending dose study, in which participants were enrolled into one of seven rifasutenizol dose groups (50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, or 1000 mg) and were randomly assigned in a 4:1 ratio to study drug or placebo. Trial 2 was a phase 1, double-blind, randomised, placebo-controlled, multiple ascending dose study, in which patients were enrolled into one of three rifasutenizol dose groups (200 mg, 400 mg, or 600 mg) and were randomly assigned in a 3:1 ratio to study drug or placebo. Trial 3 was a phase 2a, open-label, randomised, multiple-dose, dose-finding study in which patients enrolled into one of four cohorts were randomly assigned in a 1:1:1:1 ratio to a rifasutenizol dual or triple regimen. Trial 4 was a phase 2b, open-label, randomised, multiple-dose, regimen exploration study, in which patients enrolled into one of five cohorts were randomly assigned in a 2:2:1:1:2 ratio to a rifasutenizol dual therapy, triple therapy, or a control cohort. Block randomisation (block size 4 or 8) was used in all four trials. The key primary endpoints for trials 1, 2, and 3 were the tolerability, safety, and pharmacokinetics of rifasutenizol. For trial 4, the primary endpoint was the eradication rate of H pylori. These four trials were registered at ClinicalTrials.gov (NCT06081699, NCT06081712, NCT06076681, and NCT06076694) and chinadrugtrials.org.cn (CTR20190734, CTR20192553, CTR20212050, and CTR20220625) and are completed.FINDINGSBetween May 9, 2019, and Sept 14, 2022, 78 healthy participants (trial 1: n=10 per cohort in a 4:1 rifasutenizol:placebo ratio; and an additional eight for the food-effect cohort) and 168 patients with asymptomatic H pylori infection (trial 2: n=16 per cohort in a 3:1 rifasutenizol:placebo ratio; trial 3: n=10 per cohort; trial 4: n=10 or n=20 per cohort) were enrolled in the four clinical trials. Single doses of rifasutenizol (50-1000 mg) and multiple doses of rifasutenizol (200 mg to 600 mg, twice a day), either as monotherapy or co-administered with rabeprazole and amoxicillin, showed favourable safety and tolerability profiles. Most adverse events were mild, and no serious adverse events were reported. Rifasutenizol demonstrated a linear pharmacokinetic profile over the dose range of 50-800 mg, and there were no apparent pharmacokinetic interactions between rifasutenizol and the co-administrated drugs. Food intake slightly elevated the area under the plasma concentration-time curve (AUC) of rifasutenizol, and the geometric mean of AUC from time 0 to the last timepoint with a quantifiable concentration (AUC_0-t) and AUC from time 0 to infinity (AUC_0-∞) in the fed state were 1·334 and 1·396 times of those in the fasted state, respectively. There was mild accumulation after continuous administration of rifasutenizol, and the R_ac(AUC) of rifasutenizol 400 mg in the dual and triple regiments in trial 3 were 1·37 and 1·49, respectively. In trial 3, the eradication rates of H pylori with 200 mg, 400 mg, or 600 mg of rifasutenizol in combination with rabeprazole, twice a day for 14 days, were 0% (95% CI 0-31), 30% (7-65), and 40% (12-74), respectively, identifying rifasutenizol 400 mg as the effective dose. In trial 4, H pylori eradication rates with the triple regimen in cohort A (400 mg rifasutenizol, 20 mg rabeprazole sodium, and 1 g amoxicillin) twice a day for 14 days was 95% (95% CI 74-100), and triple therapy (600 mg rifasutenizol, 20 mg rabeprazole sodium, and 1 g amoxicillin) three times a day for 7 days was 100% (69-100).INTERPRETATIONRifasutenizol monotherapy and combination therapy was generally safe and well tolerated in healthy participants and patients with H pylori infection. A triple regimen of 400 mg rifasutenizol capsules, 20 mg rabeprazole sodium enteric-coated tablets, and 1 g amoxicillin capsules twice a day for 14 days showed promising efficacy as a new treatment regimen for H pylori infection.FUNDINGTenNor Therapeutics and National Natural Science Foundation of China.TRANSLATIONFor the Chinese translation of the abstract see Supplementary Materials section.

247

项与雷贝拉唑钠相关的新闻（医药）

2024-11-18

·药智网

30年首个！幽门螺杆菌「首创新药」更新进展

今日（11月18日），丹诺医药宣布其用于治疗幽门螺杆菌感染的全球首创新药TNP-2198成功完成III期临床试验并达到研究预设的主要终点指标，同铋剂四联相比体现多方面优势。丹诺医药创始人马振坤博士表示：“TNP-2198是30年以来全球第一个专门针对幽门螺杆菌感染开发的抗菌新药，具有独特的多靶点协同作用机制。” 丹诺医药官微显示，这是一项多中心、随机、双盲、铋剂四联对照的III期临床试验，旨在评价TNP-2198联合阿莫西林和雷贝拉唑三联方案在初治患者中根除幽门螺杆菌的有效性和安全性。这项研究由北京大学第三医院周丽雅教授牵头，在全国40家医院开展。研究共纳入700例既往未接受过根除治疗、碳-13尿素呼气试验（UBT）阳性并经组织学确认的幽门螺杆菌感染者，患者按1:1随机分配至TNP-2198三联方案（试验组）或铋剂四联方案（对照组），接受每天2次，连续14天治疗，有效性终点为治疗结束后4~6周的UBT检测结果。这项III期临床试验的整体执行情况良好，脱落率仅为3%，服药依从性高达96%，基线幽门螺杆菌培养成功率高达87%。试验组和对照组在人口学及基线药敏特征方面没有影响研究结果的显著差异。本研究中感染者克拉霉素、甲硝唑、左氧氟沙星和阿莫西林的耐药率分别达到41%、68%、35%和8%，与近期文献报道结果一致，表明中国幽门螺杆菌感染者中耐药问题严重。研究中未分离到对TNP-2198的耐药菌株。有效性的主要分析人群为改良意向治疗分析集（mITT），即在随机分组后接受至少一次试验用药品治疗的感染者。TNP-2198三联方案在mITT人群中对幽门螺杆菌的根除率超过90%，高于铋剂四联对照（92.0%vs.87.9%，差值4.1%，非劣检验P<0.0001，优效检验P=0.0338）。在符合方案集（PP），即未发生影响疗效分析的重大方案违背的感染者中，TNP-2198三联方案的根除率同样高于铋剂四联（93.7%vs.90.3%，差值3.4%，非劣检验P<0.0001，优效检验P=0.0563）。在微生物学意向治疗分析集（Micro-ITT），即基线幽门螺杆菌培养阳性且有药敏试验结果的感染者中，基于药敏试验结果的任何抗生素耐药亚组（即对目前用于幽门螺杆菌根除的5种抗生素中的任何一个耐药）分析表明，TNP-2198三联方案对幽门螺杆菌的根除率仍超过90%，同样高于铋剂四联方案，与主要分析人群结果一致，表明TNP-2198三联方案对耐药感染具有良好的根除效果。 TNP-2198三联方案组在治疗期间发生的不良事件（TEAE）、试验用药品相关TEAE、3级及以上TEAE的发生率，均低于铋剂四联方案组，且大部分为1级，未出现与试验用药品相关的严重不良事件（SAE），表明TNP-2198三联方案具有良好的安全耐受性。丹诺医药官微显示，TNP-2198是一个具有独特多靶点协同作用机制的抗菌新药候选物，拥有克服抗生素耐药、降低耐药频率和对慢代谢球形菌有效的优势，曾获得国家十三五“重大新药创制”科技重大专项的支持。丹诺医药已经完成TNP-2198的7项I-III期临床试验，并取得积极结果。丹诺医药拥有TNP-2198在美国的新药临床试验（IND）许可、美国FDA合格抗感染产品（QIDP）和快速通道（Fast Track）资格认定。声明：本内容仅用作医药行业信息传播，不代表药智网立场。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 史蒂文阅读原文，是受欢迎的文章哦

临床3期临床结果

2024-11-18

·药渡Daily

丹诺医药首创新药TNP-2198临床 III期试验达到主要终点

今日（11月18日），丹诺医药官网宣布，用于治疗幽门螺杆菌感染新药TNP-2198（Rifasutenizol，瑞法舒坦唑）成功完成III期临床试验并达到研究预设的主要终点指标，同铋剂四联相比体现多方面优势。 TNP-2198是全球首创新，具有独特的多靶点协同作用机制，拥有克服耐药和降低耐药频率的优势，对国内外不同地区分离的幽门螺杆菌临床菌株，包括耐药菌株保持良好的杀菌活性。临床III期试验旨在评价TNP-2198联合阿莫西林和雷贝拉唑三联方案在初治患者中根除幽门螺杆菌的有效性和安全性。临床研究结果表明：有效性的主要分析人群为改良意向治疗分析集（mITT），即在随机分组后接受至少一次试验用药品治疗的感染者。TNP-2198三联方案在mITT人群中对幽门螺杆菌的根除率超过90%，高于铋剂四联对照（92.0% vs 87.9%，差值4.1%，非劣检验P<0.0001，优效检验P=0.0338）。在符合方案集（PP），即未发生影响疗效分析的重大方案违背的感染者中，TNP-2198三联方案的根除率同样高于铋剂四联（93.7% vs 90.3%，差值3.4%，非劣检验P<0.0001，优效检验P=0.0563）。在微生物学意向治疗分析集（Micro-ITT），即基线幽门螺杆菌培养阳性且有药敏试验结果的感染者中，基于药敏试验结果的任何抗生素耐药亚组（即对目前用于幽门螺杆菌根除的5种抗生素中的任何一个耐药）分析表明，TNP-2198三联方案对幽门螺杆菌的根除率仍超过90%，同样高于铋剂四联方案，与主要分析人群结果一致，表明TNP-2198三联方案对耐药感染具有良好的根除效果。参考文献 1. 丹诺医药官网

临床3期临床2期微生物疗法临床结果

2024-11-18

·医药观澜

丹诺医药幽门螺杆菌新药3期临床试验达到主要终点

2024年11月18日，丹诺医药宣布其用于治疗幽门螺杆菌感染的潜在“first-in-class”新药TNP-2198成功完成3期临床试验并达到研究预设的主要终点指标，同铋剂四联相比体现多方面优势。这是一项多中心、随机、双盲、铋剂四联对照的3期临床试验，旨在评价TNP-2198联合阿莫西林和雷贝拉唑三联方案在初治患者中根除幽门螺杆菌的有效性和安全性。这项研究由北京大学第三医院周丽雅教授牵头，在中国40家医院开展。研究共纳入700例既往未接受过根除治疗、碳-13尿素呼气试验（UBT）阳性并经组织学确认的幽门螺杆菌感染者，患者按1:1随机分配至TNP-2198三联方案（试验组）或铋剂四联方案（对照组），接受每天2次，连续14天治疗，有效性终点为治疗结束后4~6周的UBT检测结果。这项3期临床试验的整体执行情况良好，脱落率仅为3%，服药依从性高达96%，基线幽门螺杆菌培养成功率高达87%。试验组和对照组在人口学及基线药敏特征方面没有影响研究结果的显著差异。本研究中感染者克拉霉素、甲硝唑、左氧氟沙星和阿莫西林的耐药率分别达到41%、68%、35%和8%，与近期文献报道结果一致，表明中国幽门螺杆菌感染者中耐药问题严重。研究中未分离到对TNP-2198的耐药菌株。有效性的主要分析人群为改良意向治疗分析集（mITT），即在随机分组后接受至少一次试验用药品治疗的感染者。TNP-2198三联方案在mITT人群中对幽门螺杆菌的根除率超过90%，高于铋剂四联对照（92.0% vs. 87.9%，差值4.1%，非劣检验 P<0.0001，优效检验 P=0.0338）。在符合方案集（PP），即未发生影响疗效分析的重大方案违背的感染者中，TNP-2198三联方案的根除率同样高于铋剂四联（93.7% vs. 90.3%，差值3.4%，非劣检验 P<0.0001，优效检验 P=0.0563）。在微生物学意向治疗分析集（Micro-ITT），即基线幽门螺杆菌培养阳性且有药敏试验结果的感染者中，基于药敏试验结果的任何抗生素耐药亚组（即对目前用于幽门螺杆菌根除的5种抗生素中的任何一个耐药）分析表明，TNP-2198三联方案对幽门螺杆菌的根除率仍超过90%，同样高于铋剂四联方案，与主要分析人群结果一致，表明TNP-2198三联方案对耐药感染具有良好的根除效果。 TNP-2198三联方案组在治疗期间发生的不良事件（TEAE）、试验用药品相关TEAE、3级及以上TEAE的发生率，均低于铋剂四联方案组，且大部分为1级，未出现与试验用药品相关的严重不良事件（SAE），表明TNP-2198三联方案具有良好的安全耐受性。这项临床试验的主要研究者，北京大学消化疾病研究中心主任、中华医学会消化病学分会副主任委员周丽雅教授说：“幽门螺杆菌根除的挑战是抗生素耐药问题，近年来通过改进抑酸效果，特别是钾离子竞争性酸阻滞剂P-CAB的使用，对提高铋剂四联的根除效果有所帮助，但并没有从根本上解决日趋严重的抗生素耐药问题。作为具有独特作用机制的抗菌新药，TNP-2198的这项3期临床试验结果令人兴奋，无论是在抗生素敏感还是耐药人群中TNP-2198三联方案均实现90%以上根除率，为幽门螺杆菌根除提供了一个全新的解决方案。” 丹诺医药创始人马振坤博士表示：“TNP-2198是30年以来全球第一个专门针对幽门螺杆菌感染开发的抗菌新药，具有独特的多靶点协同作用机制。这项III期临床试验结果表明，TNP-2198三联方案同铋剂四联相比具有多方面优势，无论是在抗生素敏感还是耐药感染者中均实现90%以上根除率，实现幽门螺杆菌根除首战即决战的目标，为在胃癌高危人群中进行幽门螺杆菌筛查-根除、预防胃癌，提供了一个安全、有效、简便，特别是无需药敏试验、能够与UBT检测无缝衔接的根除方案。” TNP-2198是一个具有独特多靶点协同作用机制的抗菌新药候选物，拥有克服抗生素耐药、降低耐药频率和对慢代谢球形菌有效的优势。丹诺医药已经完成TNP-2198的7项1~3期临床试验，并取得积极结果。丹诺医药拥有TNP-2198在美国的新药临床试验（IND）许可，并获得美国FDA授予合格抗感染产品（QIDP）和快速通道（Fast Track）资格。参考资料： [1] 丹诺医药新闻稿内容来源于网络，如有侵权，请联系删除。

临床结果微生物疗法

100 项与雷贝拉唑钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00724	雷贝拉唑钠	A02BC04	DBSALT000552

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
糜烂性胃食管反流病	美国	CHARTWELL RX SCIENCES LLC	2013-11-08
幽门螺杆菌感染	美国	CHARTWELL RX SCIENCES LLC	2013-11-08
螺杆菌感染	韩国	Genuone Sciences, Inc.	2000-02-21
胃溃疡	韩国	Genuone Sciences, Inc.	2000-02-21
十二指肠溃疡	美国	Waylis Therapeutics LLC	1999-08-19
胃食管反流	美国	Waylis Therapeutics LLC	1999-08-19
Zollinger-Ellison综合征	美国	Waylis Therapeutics LLC	1999-08-19

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
十二指肠溃疡	药物发现	美国	Aytu Biopharma, Inc.	2013-03-26
胃食管反流	药物发现	美国	Aytu Biopharma, Inc.	2013-03-26
Zollinger-Ellison综合征	药物发现	美国	Aytu Biopharma, Inc.	2013-03-26
非糜烂性胃食管反流病	药物发现	日本	Eisai Co., Ltd.	2004-09-01
非糜烂性反流病	药物发现	日本	Eisai Co., Ltd.	2004-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05918822 (CTgov)	临床1期	-	32	Maribavir Pediatric Powder-for-oral Suspension Formulation+rabeprazole	繭鏇蓋鹹餘艱夢衊簾鬱(壓製鹽鹽衊網鹽襯鏇衊) = 簾憲製膚糧壓壓製膚廠繭壓網鑰餘窪衊製構糧 (繭簾膚簾廠網鏇積獵襯, 壓選鹹齋廠網顧糧繭鬱 ~ 鹹衊餘鹹廠網選選夢獵) 更多	-	2024-09-26
NCT06076694 (CTgov)	临床2期	幽门螺杆菌感染	80	TNP-2198+Amoxicillin+Rabeprazole Sodium (Group A)	選淵築製願衊壓窪膚獵(餘鏇鏇範網範鬱選鹽獵) = 鹽艱衊繭鑰鹹鑰艱夢餘齋艱衊衊夢蓋顧壓廠襯 (夢醖齋獵鬱齋鏇衊衊網, 觸積夢襯顧鹽壓襯蓋餘 ~ 醖淵蓋廠願蓋製網積齋) 更多	-	2023-12-12
				TNP-2198+Amoxicillin+Rabeprazole Sodium (Group B)	選淵築製願衊壓窪膚獵(餘鏇鏇範網範鬱選鹽獵) = 製網構憲鏇膚艱觸淵衊齋艱衊衊夢蓋顧壓廠襯 (夢醖齋獵鬱齋鏇衊衊網, 製網簾衊繭壓鬱醖積遞 ~ 糧壓願顧鏇蓋鹽壓衊製) 更多
NCT06076681 (CTgov)	临床1/2期	幽门螺杆菌感染	40	TNP-2198+Rabeprazole Sodium (Group A)	艱築觸窪淵蓋獵糧醖構(網膚鏇鏇選醖製廠衊憲) = 夢憲構簾醖網構糧製壓憲蓋鑰鹽獵齋積齋網製 (鑰廠憲壓夢艱繭憲觸繭, 構積餘製鏇構遞窪選範 ~ 鬱廠鏇襯顧範鏇窪蓋獵) 更多	-	2023-11-22
				TNP-2198+Rabeprazole Sodium (Group B)	艱築觸窪淵蓋獵糧醖構(網膚鏇鏇選醖製廠衊憲) = 窪壓遞衊淵壓糧簾醖襯憲蓋鑰鹽獵齋積齋網製 (鑰廠憲壓夢艱繭憲觸繭, 觸網繭壓醖鹹鑰鹹齋積 ~ 餘顧遞鹹蓋膚鹽壓艱範) 更多
NCT02605395 (CTgov)	临床4期	胃肠道疾病	70	Idiazole (Idiazole 20 mg)	襯製製襯獵顧廠餘鑰憲(築餘鬱蓋願襯膚鹹鹽築) = 構顧遞鏇範醖繭製顧遞淵製糧獵築鹹鏇選網鹹 (衊遞顧鑰築網願襯窪繭, 齋餘遞築繭衊範鏇製膚 ~ 製構窪範鹹觸淵憲願鹹) 更多	-	2018-10-01
				Pariet (Pariet 20 mg)	襯製製襯獵顧廠餘鑰憲(築餘鬱蓋願襯膚鹹鹽築) = 鹽壓積餘糧鹽壓繭憲艱淵製糧獵築鹹鏇選網鹹 (衊遞顧鑰築網願襯窪繭, 齋廠簾鑰製淵憲製範鑰 ~ 築簾鹹簾窪壓鑰廠壓憲) 更多
NCT01202071 (CTgov)	临床2期	-	24	Rabeprazole Sodium (Rabeprazole Sodium 5 mg Tablet)	淵築夢糧醖膚遞繭壓觸(網範遞網範餘鏇製淵願) = 鏇齋製襯積選齋醖鹽遞簾窪積廠鹽範製鏇簾鏇 (醖鑰選鑰齋衊窪簾製醖, 簾鏇顧蓋獵構膚鑰築積 ~ 蓋鏇醖鑰窪繭夢廠壓網) 更多	-	2012-11-27
				Rabeprazole Sodium (Rabeprazole Sodium 10 mg Tablet)	淵築夢糧醖膚遞繭壓觸(網範遞網範餘鏇製淵願) = 艱顧簾憲糧選淵蓋範遞簾窪積廠鹽範製鏇簾鏇 (醖鑰選鑰齋衊窪簾製醖, 壓獵壓觸鬱顧製蓋範鹹 ~ 繭蓋積願窪淵鹽選廠願) 更多
NCT00770913 (CTgov)	临床2/3期	反流性食管炎	337	E3810 (E3810 20 mg Once Daily)	積壓夢糧膚鹹蓋艱製願(顧築壓構廠鏇壓壓觸憲) = 鏇襯齋製壓繭鏇壓餘選淵願構簾鹹網艱鹽壓夢 (壓蓋糧廠鏇鬱積積願淵, 選築窪構鹽獵襯鹽鏇鏇 ~ 顧糧夢構淵餘鏇蓋糧醖) 更多	-	2012-04-13
				E3810 (E3810 10 mg Twice Daily)	積壓夢糧膚鹹蓋艱製願(顧築壓構廠鏇壓壓觸憲) = 膚艱糧壓膚遞遞鹽選衊淵願構簾鹹網艱鹽壓夢 (壓蓋糧廠鏇鬱積積願淵, 襯廠蓋憲壓網製廠繭襯 ~ 夢醖壓構顧鹽鏇觸遞齋) 更多
IAS2008	N/A	-	93	Ritonavir 100 mg film-coated tablet	憲製獵簾廠襯構網壓簾(襯構淵膚簾顧窪簾願衊) = 淵醖構廠鏇獵廠鹹鏇構壓膚鬱醖構遞鏇醖廠築 (鹽鹹艱壓襯鹽範願鹽鑰 ) 更多	-	2008-01-01
				Ritonavir 100 mg soft gelatin capsule	憲製獵簾廠襯構網壓簾(襯構淵膚簾顧窪簾願衊) = 築網衊鹽獵鏇糧餘夢廠壓膚鬱醖構遞鏇醖廠築 (鹽鹹艱壓襯鹽範願鹽鑰 ) 更多
IAS2003	N/A	HIV感染	-	Reverset 0 mg	(顧網顧鹽糧顧顧範衊夢) = 鏇築願觸廠願衊膚窪製憲蓋鬱觸鑰衊襯網鏇醖 (積構構襯廠網糧顧憲鹹, 0.2) 更多	-	2003-01-01
				Reverset 50 mg (enteric-coated tablets)	(顧網顧鹽糧顧顧範衊夢) = 壓壓構觸蓋壓獵鬱選淵憲蓋鬱觸鑰衊襯網鏇醖 (積構構襯廠網糧顧憲鹹, 1.6)